Nurix Therapeutics, Inc. Stock Analysis & AI Score
Nurix Therapeutics, Inc. (NRIX) has an ST Score of 41.7 (C), driven by its Momentum (B+) and held back by its Profitability (D+). Analysts rate it Buy with a $34.67 price target (+46.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Nurix Therapeutics, Inc. (NRIX) has an ST Score of 41.7 (C), driven by its Momentum (B+) and held back by its Profitability (D+). Analysts rate it Buy with a $34.67 price target (+46.6% upside).
- Strongest
- MomentumB+
- Weakest
- ProfitabilityD+
All factor grades
- MomentumB+
- ForecastB
- SentimentC+
- ValuationC
- Financial StrengthC
- GrowthC
- ProfitabilityD+
- Piotroski2/9
Contact
NRIX stock: frequently asked questions
What is NRIX's ST Score?
Nurix Therapeutics, Inc. (NRIX) has an ST Score of 41.7 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is NRIX a buy, hold, or sell?
Analysts rate NRIX a Buy, with a price target of $34.67 (+46.6% vs the current price). Our ST Score grades it C (41.7/100). The ST Score is a data-driven signal, not a recommendation.
What are NRIX's factor grades?
Valuation C, Profitability D+, Financial Strength C, Momentum B+, Growth C, Forecast B, Sentiment C+.
What is NRIX's valuation grade?
Nurix Therapeutics, Inc. (NRIX) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is NRIX's growth grade?
Nurix Therapeutics, Inc. (NRIX) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is NRIX's profitability grade?
Nurix Therapeutics, Inc. (NRIX) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is NRIX's financial strength grade?
Nurix Therapeutics, Inc. (NRIX) earns a financial strength grade of C, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for NRIX?
The average analyst price target for Nurix Therapeutics, Inc. (NRIX) is $34.67 from 19 analysts, which is +46.6% versus the recent price of $23.65.
What is NRIX's Piotroski score?
Nurix Therapeutics, Inc. (NRIX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.